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Review Article
Exosomes as a new pain biomarker
opportunity
Simona D’Agnelli1 , Maria C Gerra2, Elena Bignami1, and
Lars Arendt-Nielsen2
Abstract
Exosomes are extracellular microvesicles implicated in intercellular communication with ability to transfer cargo molecules,
including protein, lipids, and nucleic acids, at both close and distant target sites. It has been shown that exosomes are
implicated in physiological and pathological processes. In recent years, the interest on exosomes’ role in many pain states has
increased. Their involvements in pain processes have been demonstrated by studies on different chronic pain diseases, both
inflammatory and neuropathic, such as osteoarthritis, rheumatoid arthritis, inflammatory bowel diseases, neurodegenerative
pathologies, complex regional pain syndrome, and peripheral nerve injury. Animal and clinical studies investigated exosomes-
based treatments, showing their ability to improve painful symptoms with fewer side effects, with potential immunopro-
tective and anti-inflammatory effect. Specific molecular patterns characterize exosomes’ cargo according to the cellular
origin, epigenetic modifications, environmental state, and stressor factors. Therefore, the identification of specific cargo’s
profile associated to pain states may lead to recognize specific pathological states and to consider the use of exosomes as
biomarkers of diseases. Furthermore, exosomes’ ability to transfer information and their presence in many accessible
biological fluids suggest a potential use as novel non-invasive therapeutic tools in pain field.
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Introduction
Chronic pain is one of the most common worldwide
problem, which affects 20% to 25% of people, especially
older than 65 years.1 In recent years, the interest in
extracellular circulation vesicles and their role in differ-
ent pain states are increased, and the most attention
among them was attracted by exosomes. Exosomes are
nanosized vesicles of endosomal origin fused with the
plasma membrane. They have been demonstrated to
mediate the transfer of cargo including proteins, lipids,
and nucleic acids into the extracellular environment or in
target cells.2 The fact that exosomes have been detected
in many body fluids (e.g. blood,3 cerebrospinal fluid
(CSF),4 urine,5 sperm,6 breast milk,7 and nasal secre-
tions8) highlights their role as intercellular communica-
tion mediators and, thanks to their transfer ability, they
are involved in both pathological and physiological pro-
cesses. Exosomes’ involvement in pain processes have
been demonstrated by studies on different chronic pain
diseases, in particular osteoarthritis (OA),9,10 rheuma-
toid arthritis (RA),11 inflammatory bowel diseases
(IBDs),12 neurodegenerative pathologies,13 and complex
regional pain syndrome (CRPS).14 From some of these
studies, exosomes appear to be a possible novel thera-
peutic strategy,15 transferring cargo in close and distance
target cells. They have been even identified as a promis-
ing treatment able to improve painful symptoms with
fewer side effects,15 with potential immunoprotective16
and anti-inflammatory role.10 Moreover, it has been
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found that exosomes might represent a tool to distin-
guish subgroups of patients with higher possibility to
benefit from specific treatments.14 In this narrative
review, we provide an overview of exosomes in pain
field present in literature. Possible associations between
exosomes and painful diseases are discussed. The aims
are to discuss the physiological role of exosomes for
potential use as (1) biomarkers and/or (2) novel thera-
peutic tools.
Physiological role of exosomes
Exosomes are the smallest extracellular vesicles, 30 to
100 nm in size, released by various cell types and gener-
ated by the inward budding of multivesicular endosomes
membrane, containing intraluminal vesicles (ILVs), to
the plasma membrane.17 This fusion requires the
involvement of small GTPases of the Rab family and
induces the release of the content including ILVs; once
shed, the ILVs are called exosomes. Compared to other
extracellular vesicles, such as microvesicles or ectosomes,
exosomes differ in size, lipids composition, content, and
cellular origin. By transmission electron microscopy, it
has been suggested that exosomes have a cup morphol-
ogy and a bilayer lipid structure.18 The bilayer mem-
brane confers stability to the structure, protects cargo
by degradation processes, and allows exosomes’
moving across biological barriers, thanks to membrane
adhesive proteins.19
Exosomes have a specific gene expression profile by
which it is possible to detect and differentiate them from
other extracellular vesicles. In particular, this specific
protein pattern includes tetraspanins (CD9, CD63,
CD81, and CD82), heat shock proteins (HSP60,
HSP70, and HSP90), tumor susceptibility gene 101 pro-
tein (TSG101), and ALG-2-interacting protein X
(ALIX).20 Their biogenesis within a cell seems to be
mediated by a complex composed of four multiprotein
sub-complexes that also guides the sorting of the intra-
cellular cargo, the Endosomal Sorting Complex
Required for Transport (ESCRT).21 The intercellular
communication seems to involve two different mecha-
nisms: the first one precisely based on ESCRT machin-
ery in combination with other players, such as syndacans
transmembrane protein, cytosolic adaptor syntenin, and
the accessory protein ALIX.22 Syndecans with their hep-
aran sulphate polysaccharide chains mediate many of
surface signaling events, connecting with cytosolic adap-
tor syntenin, that in its turn interacts directly with
ALIX.23 ALIX binds ESCRT-III, one of multiprotein
sub-complex, allowing the intraluminal budding of
endosomal membranes.22
The second method of intercellular communication
proposed is an alternative ESCRT-independent
mechanisms that involve tetraspanins and lipids to medi-
ate the sorting of specific molecules into exosomes.24
These membrane vesicles are present in numerous
biological fluids3–8 and different conditions can induce
their release, both physiologically and pathologically.
Their cargo is characterized by a broad range of mole-
cules including proteins, messenger RNA, long non-
coding RNA, circular RNA, DNA, and lipids,24 which
depend on cellular origin and enviromental state. The
protein composition of exosomes enables to get rid of
obsolete and toxic material; in fact, many misfolded and
prion proteins involved in the development of neurode-
generative diseases are released and exported through
exosomes.25 Therefore, these proteins have a quality
control role and are involved in preservation of homeo-
stasis. Similarly, exosomes participate in the regulation
of intracellular RNA homeostasis by promoting the
release of misfolded or degraded RNA products.26
Exosomes are implicated in the immune response carry-
ing, for example, antigens from the cells from which they
originate.20 In particular, unidirectional transfer of
micro RNA (miRNA) from the T cell to the antigen-
presenting cells was demonstrated.27 They have been
shown to induce targeted endothelial cell migration
through the enhanced secretion of monocytic miR-
150,28 highlighting their role affecting recipient cells
function. The exosome-mediated transfer of RNA to
silence target genes between cells was demonstrated.29
Exosomes are also involved in lipid homeostasis sup-
porting the low-density lipoprotein release, as seen in
Niemann-Pick type C disease.30
Exosomes in different chronic pain
conditions
Chronic pain is a complex multifactorial disease with a
serious impact on the quality of life due to a variety of
associated symptoms such as anxiety, depression, insom-
nia, and other mood disorders. The lack of a precise
understanding of its pathophysiology, early diagnosis
interventions, and effective treatments can result in a
significant morbidity and mortality.31
Nowadays, the available treatments are based on the
use of opioids and nonsteroidal anti-inflammatory
drugs,32 addressed to reduce symptoms without com-
plete recovery, often causing side effects such as consti-
pation, addiction, impairment of immune system, and
opioid-induce hyperalgesia.33 Furthermore, there is an
interindividual variability on therapy’s response, with
relevant implications in terms of efficacy and safety.34
Research on both potential treatments and early diagno-
sis biomarkers is essential, in light of the urgent need to
minimize the severe effects of chronic pain in individuals
and in the society. Many researchers are involved in
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biomarkers discovery in pain field and many data have
been obtained at “-omics” level (glycomics, Activomics,
genome-wide association studies, and epigenomics),35,36
but other studies are needed to be validated and to be
transferred in clinical practice. Because of exosomes’
ability to transfer information from an origin cell to a
recipient cell2 and their presence in many accessible bio-
logical fluids,3–8 they may reveal novel and promising
insights in the pain field. In the last years, exosomes
have been increasingly found associated with pain con-
ditions. An overview of the studies investigating exo-
somes in neuropathic and inflammatory chronic pain
conditions is reported in Table 1.
Exosome-based treatments
Exosomes of mesenchymal stem cells (MSCs) have been
shown to relieve painful symptoms, with an analgesic
action in several chronic pain models and fewer side
effects.15 The use of MSCs has been suggested as a treat-
ment for peripheral nerve injury,19 but their therapeuti-
cally effects are linked to their exosomes which can
transfer miRNAs cargo to target neurons, in order to
favorite axonal growth and neural survival.37 The mech-
anisms with which these exosomes act are until now
unclear, but the demonstrated presence of many neuro-
trophic factors between MSC-exosomes’ cargos, such as
glial cell-derived neurotrophic factor (GDNF), fibro-
blast growth factor-1 (FGF-1), brain-derived neurotro-
phic factor (BDNF), insulin-like growth factor-1 ( IFG-
1) and nerve growth factor (NGF), supports the idea of
their potential efficacy in peripheral nerve injury treat-
ment.19 Furthermore, Simeoli et al. have suggested the
use of miR-21-5p antagomir to regulate the
iperexpression of miR-21-5p found in neuronal exo-
somes of dorsal root ganglia, after nerve injury in
mice. Overexpression of MiR-21-5p supports pro-
inflammatory phenotype of macrophages attracted on
the site of damage, while intrathecal delivery of a
miR-21-5p antagomir appears to avoid an extension of
inflammatory condition and neuropathic hypersensitivi-
ty onset.38
Exosomes appear to be involved in immune regula-
tion and antigen presentation,39,40 thanks to presence
among their cargos of immunomodulatory mediators
such as transforming growth factor, interferon-c, indole-
amine 2,3-dioxygenase, prostaglandin E2 (PGE2), heme
oxygenase-1, and interleukin-10 (IL-10).41Macrophage-
derived exosomes have been shown to have an immuno-
suppressive role; in particular, Jiang et al. demonstrated
that the transfer of exosomes produced by intestinal epi-
thelial cells into IBD mice could induce regulatory T
cells and immunosuppressive dendritic cells and subse-
quent decrease the severity of the disease.12
Exosomes derived from immune cells or nervous cells
also have the ability to cross blood–brain barrier with
neuroprotective and tissue repair effects.42 This ability
suggests the possibility to use exosomes to transfer spe-
cific drug molecules acting in target tissue to resolve
cerebral injury.43 Many studies have been conducted to
verify the exosomes’ capacity to cross blood–brain bar-
rier such as Alvarez-Erviti et al. who demonstrated that
small interfering RNAs mediated by exosomes of den-
dritic cells interfered in the Alzheimer’s treatment in
mouse brain model. Then, it could be explained with
exosomes’ ability to passes the barrier and delivers
their cargos to target cells.44
Exosome-based biomarker diagnosis
Exosomes could represent novel non-invasive bio-
markers of specific pain diseases in order to obtain an
early diagnosis. The molecular pattern inside exosomes
is different according to the cellular origin, epigenetic
modifications, environmental state, and stressor factors.
Therefore, identification of specific cargo’s profile asso-
ciated to pain states might lead to distinguish a specific
pathological state from a healthy state and to use exo-
somes as biomarkers of the diseases. Human studies on
CRPS identified specific miRNAs that could be useful to
identify subgroup of patients in order to find personal-
ized therapeutic strategies,14 for example, low level of
miR-338-5p in CRPS patients could identify poor res-
ponders to plasmapheresis treatment; it could suggest
clinicians to evaluate alternative strategies.45 Moreover,
in IBD patients’ exosomes, an overexpression of
annexine-1 during inflammatory process than healthy
controls has been found, highlighting its potential role
as diagnosis biomarker.46
Thanks to their capability to transfer miRNAs, exo-
somes also have an important role in neuronal mecha-
nisms such as synaptic plasticity, neurogenesis, and
neuronal differentiation.47 About their involvement in
neurodegenerative diseases,13 often the research of bio-
markers is conducted on blood sample, thanks to its easy
collection protocol without risks of an invasive proce-
dure; however, some limits about blood biomarkers util-
ity were found.48 One of them in particular is that blood
biomarkers are not exclusively central nervous system
(CNS)-specific and, then, they could be impaired with
their diagnostic and prognostic values. On the contrary,
CSF sample collection is an invasive procedure with a
lumbar puncture, but as CSF is directly connected with
brain and spinal cord, possible molecular changes in
their microenvironments are highlighted by its composi-
tion, making it a better source for biomarkers research
of neuronal diseases than blood.49
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Table 1. Overview of studies investigating exosomes role in neuropathic and inflammatory chronic pain conditions.
Specific conditions Samples Main findings PMID
Chronic
Neuropathic
pain
Spinal cord injury Mouse SCI model Ccl3 transfer from Schwann cells to blood
through exosomes.
29164149
Peripheral neuropathies Rat Schwann cell
exosomes and
human serum
p75 and NCAM subtype-specifically
expressed in the sera of patients with
peripheral neuropathy.
31353867
Sciatic nerve injury Mice model, chronic
constriction injury
of the sciatic nerve
Release of exosomes from mPFC and NAc
has elevated the pain sensations in the
subjected mice.
31981720
Sciatic nerve injury Mice model, partial
sciatic nerve ligation
Expression level of miR-21 significantly
increased in exosomes extracted from
blood of nerve-ligated mice
26990296
Nerve injury Mouse model induced
by SNI
Upregulation of C5a and ICAM-1
in exosomes from SNI model
compared to control.
31669360
Peripheral axon injury Mice, exosomal
fraction of cultured
DRG
Neuron–macrophage communication pro-
posed as analgesic strategy and miR-21-
5p proposed as specific target of the
exosome cargo.
29176651
Complex regional
pain syndrome
Human subjects hsa-miR-223- 5p increased in plasma exo-
somes in subjects with fracture with
normal healing compared to subjects
developing CRPS and healthy controls.
31095096
Human subjects;
HEK293 cells
17 miRNAs identified differentially
expressed before and after therapy in
CRPS patients; hsa-miR-338-5p regu-
lates IL-6 mRNA and protein levels in
vitro.
30871575
HEK293 cells Gene expression changes in recipient cells
following the uptake of
exosomes enriched in miR-939.
31489147
Chronic
Inflammatory
Pain
Rheumatoid arthritis Synovial exosomes
from patients with
RA
Synovial exosomes contain citrullinated
proteins
17133577
Synovial fluid from
patients with RA
and OA
Plasma miRNAs had distinct patterns from
synovial fluid miRNAs
20470394
Human mesenchymal
stem cells
Role of exosomes derived from MSCs
overexpressing miR-92a-3p in enhancing
chondrogenesis and suppressing carti-
lage degradation, through a mechanism
involving a Wnt protein.
30257711
Osteoarthritis Human mesenchymal
stem cells and rat
model
Exosomes derived from MSCs transfected
with miR-140-5p enhanced the prolifer-
ation and migration of articular chon-
drocytes and successfully prevented OA.
28042326
Human mesenchymal
stem cells
The lncRNA-KLF3-AS1 derived from
MSCs induces chondrocyte proliferation
and inhibits chondrocyte apoptosis.
30324848
Human adipose stem
cell on
chondrocytes
Exosomes derived from adipose MSC
reduce hypertrophy and dedifferentia-
tion of chondrocytes, decreasing
inflammatory mediators production,
such as TNF-a, IL-6, PGE2, and NO, and
an increasing anti-inflammatory cytokine
IL-10
23811540
(continued)
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Exosomes role in neuropathic pain
Exosomes are released and retaken by neurons depend-
ing on synaptic activity, and the reported evidence on
their inter-neuronal communication highlights the
importance to look deeper into the perspectives of exo-
somes biomarkers in neuropathic pain states. For this
purpose, many animal studies have been conducted. It
has been demonstrated that Ccl3, a chemokine potential-
ly mediating peripheral and central sensitization in neu-
ropathic pain, was transferred from Schwann cells to
peripheral blood via exosomes.43 Moreover, proteomics
analysis revealed p75 and neural cell adhesion molecule
(NCAM) exosomes proteins as potential human serum
biomarkers reflecting alterations in Schwann cells in
inflammatory and inherited neuropathy.50 In a sciatic
nerve mouse model, exosomes were also quantified
over time in the medial prefrontal cortex (mPFC) and
nucleus accumbens (NAc), revealing that their release
can mimic pain sensation-like behaviors; however, the
projections from the mPFC to the NAc are important
players in the reward circuitry and their activation inhib-
its pain behaviors. Exosomes release from these brain
areas were proposed to mediate pain threshold and allo-
dynia.51 A proteome characterization of exosomes from
mouse spared nerve injury (SNI) model suggested the
cargo sorting of vesicular proteins as a crucial step in
mediating signaling mechanisms underlying neuropathic
pain and evidenced unique patterns of proteins. In par-
ticular, significant upregulation of complement compo-
nent 5a (C5a) and Intercellular Adhesion Molecule 1 are
detected in exosomes from SNI model compared to
sham control.52 The involvement of exosomes in neuro-
pathic pain is also underlined by many studies on CRPS.
It is a chronic neuropathic pain disorder, disabling for
sensory, motor, and autonomic dysfunctions as well as
of allodynia, hyperalgesia, dystonia, and tremors.53
Ramanathan et al. have identified a different miRNA–
exosomal profile between responders and non-
responders to treatment in CRPS patients, suggesting a
potential tool to prior identify a subgroup of patients
with higher possibility to have benefit by that specific
treatment, in this case from plasmapheresis.14 In a
mouse model of CRPS, the mechanism of action of
macrophage-derived exosomes and their cargo has
been investigated. A decrement of thermal hyperalgesia
following a single injection of macrophage-derived exo-
somes has been found, suggesting a potential immuno-
protective role. In the same study, serum-derived
exosomes from CRPS patients were analyzed and 127
miRNAs were significantly different comparing CRPS
exosomes with control-derived exosomes. Among
them, three miRNAs (miR-21-3p, miR-146a, and miR-
146b), known to be involved in the control of over acti-
vation of innate immune response, are over expressed in
both murine and human model.16
Exosomes role in inflammation and pain
Inflammation is an immune response against infection or
injury that acts to restore tissue homeostasis.
Homeostasis is re-established temporally and spatially
through proinflammatory response to noxious condi-
tions and protective mechanisms driving resolution of
inflammation. However, uncontrolled or unresolved
inflammation can be active pathways of systemic inflam-
mation involved in the pathogenesis of several pain dis-
eases such OA, RA, IBDs, and neurodegenerative
Table 1. Continued.
Specific conditions Samples Main findings PMID
Mesenchymal stem cell
from adipose tissue
from healthy indi-
viduals,
Chondrocytes from
OA patients
Exosomes from adipose MSC in OA
chondrocytes decrease MMP-13
expression and enhance IL-10 and
collagen II expression.
29763932
Inflammatory
bowel disease
IBD patients’ serum An increased number of exosomes
containing ANXA-1 was found.
25664854
Rat Intestinal epithelial
cells of IBD model
Exosomes from intestinal epithelial cells
participate in maintaining of intestinal
tract immune of homeostasis.
27721471
Neuroinflam-matory
diseases
Human postmortem
prefrontal cortices
Toxic forms of aggregated proteins have
been found in brain exomes
24694258
SCI: spinal cord injury; SNI: spared nerve injury; NCAM: neural cell adhesion molecule; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; ICAM-1:
intercellular Adhesion Molecule 1; DRG: dorsal root ganglia; CRPS: complex regional pain syndrome; RA: rheumatoid arthritis; OA: osteoarthritis; miRNA:
micro RNA; MSCs: mesenchymal stem cells; TNF: tumor necrosis factor ; IL: interleukin; PGE2: prostaglandin E2; NO: nitric oxide; MMP-13: matrix
metallopeptidase 13; IBD: inflammatory bowel diseases.
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diseases. Exosomes are involved in many inflammatory
diseases due to their capabilities to transfer different
molecules as miRNAs and proteins acting on close or
distant target tissues.54 The association between inflam-
mation and the levels of specific exosomal cargo mole-
cules is a crucial step in the identification of possible
novel biomarkers of inflammatory-based diseases.
For example, RA is a chronic, inflammatory, and sys-
temic autoimmune disease caused by inflammation of
the synovium and patients are often affected by chronic
pain due to long-term joint injury.11 The onset of this
pathology is not completely clarified, but exosomes
involvement has been hypothesized as a mediating mech-
anism based on the evidence that citrullinate proteins
were found in synovial exosomes isolated from a RA
patients. Citrullination is a post translational change
essential during the conversion process of non-
immunogenic to auto-immunogenic proteins.55
Exosomes were also demonstrated to exert an anti-
inflammatory action. Indeed, exosomes derived from
adipose MSCs have a role on chondro-protective and
anti-inflammatory activities in OA.9 The action of
MSCs has been shown to trigger a decrease of inflam-
matory mediators production, such as tumor necrosis
factor a, IL-6, PGE2, and NO, and an increase of anti-
inflammatory cytokine IL-10 in the chondrocytes.56
Recent clinical trials showed a decrement of pain, an
enhancement of joint performance, and a high quality
of cartilage repair in knee OA, following MSC treat-
ment.57 Exosomes were also shown to be involved in
the IBDs, which are a set of chronic disorders that
occur when intestinal homeostasis is impaired.12 One
of the many mechanisms underlying these diseases is
represented by the immune response modulated by mac-
rophage activity. Macrophage-derived exosomes are
involved in this pathophysiological mechanism through
an immunosuppressive role. Indeed, it has been demon-
strated that exosomes of normal intestine transferred
into IBD mice are responsible of decrement of severity
of disease.12 Moreover, in IBD patients’ serum, an
increased number of exosomes containing annexine-1
was found. This protein has a key role in repairing of
mucosal damage and is overexpressed during inflamma-
tory process, representing a potential biomarker of
disease.46
Finally, exosomes are involved in both physiological
brain function and neuroinflammatory mechanisms.
Neuroinflammation is characterized by a high level of
pro-inflammatory cytokine production and glial cell
activation, causing many neurodegenerative diseases
including Parkinson’s, Alzheimer’s, and Creutzfeldt–
Jacob diseases. Exosomes transfer to neighboring cells
inflammatory molecules such as a-synuclein, amyloid b,
and prions promoting the dissemination of the disease.13
For the first time, the presence of miRNAs in CSF
exosomes has been found by Gui et al. in Parkinson’s
and Alzheimer’s patients.58 Their results have shown a
different expression of miRNAs between pathological
condition and its healthy control and between both
pathological conditions too, suggesting the possibility
to use them like biomarkers to differential diagnosis
and/or monitoring disease progression. Moreover, sev-
eral studies on CSF have found differences in the levels
of some inflammatory markers between neuropathic
pain patients and healthy controls.59,60
Conclusions and future perspectives
The high socio-economical costs related to chronic pain
are partly due to the lack of understanding of the under-
lying pathophysiology and of effective and safe treat-
ments. Exosome microvesicles are found associated to
physiological and pathological processes, involved in
many chronic pain diseases, i.e. inflammatory and neu-
ropathic pain. Thanks to their key role in intracellular
communication and their transfer ability of molecules
cargo to target cells, exosomes are considered to be
promising novel non-invasive biomarkers for mecha-
nisms underlying chronic pain. They can be collected
from different body fluids (e.g. blood and CSF) as diag-
nostic biomarkers for various chronic pain states and
may contribute to the development of new innovative
pain management opportunities. In fact, in peripheral
nerve injury treatment, it has been shown that the use
of MCS–exosomes could avoid risks caused by MSC
transplantation, like for example immune rejection,
thanks to their low immunogenicity. 61 Furthermore,
exosomes can cross biological barriers, thanks to their
membranes composition,19 and then they can be useful
like carriers for transporting drug or biological peptide
to regulate biological function of target cells. However,
until now, an effective use in clinical practice is missing
due to the absence of standardized protocol for the iso-
lation and purification of exosomes, the long time
needed to ending it and the expensive costs of labor
procedures.62 In addition, many studies show the
involvement of exosomes in many pain processes but
the molecular mechanism with which they act is until
now not completely known. Therefore, further studies
with large sample size are needed to fill these gaps and
to obtain a full knowledge of exosomes value and to
develop a valid, standardized, and cheap laboratory pro-
tocol. This is necessary to exosomes’ application in clin-
ical practice in order to go toward a precision medicine,
patient-centered, with a revolutionary impact in terms of
effectiveness, safety, ethics, and cost savings.
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